FAB: Fusion Antibodies plc - Summary | Jitta

Fusion Antibodies plc

LON:FAB

Price
£0.13
Loss Chance
58.3%
0.74JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
843 / 877
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (31)
Recent Business Performance (22)
Financial Strength (38)
Return to Shareholders (3)
Competitive Advantage (17)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningEarning loss detected in 2025
Operating MarginInconsistent
New Share IssuedMore than 50% in 5 years
CapExVery High
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
0.74
100.00%
3.24
122.46%
Life Sciences Tools and Services
5.11
96.31%
1.93
100.00%
2.03
384.69%
COMPANY DESCRIPTION
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company has a collaboration agreement with the National Cancer Institute for the use of OptiMAL. Fusion Antibodies plc was incorporated in 2000 and is based in Belfast, the United Kingdom.